Anticavity

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the prevention of dental cavities and tooth decay. It aids in strengthening teeth and provides strong cavity protection. Additionally, it contributes to freshening breath.

Dosage and Administration

Adults and children 6 years of age and older are instructed to use the rinse once daily, following the brushing of their teeth with toothpaste. The recommended method involves vigorously swishing 10 milliliters of the rinse between the teeth for a duration of 1 minute, after which the solution should be expectorated. It is imperative that the rinse is not swallowed. Additionally, patients should refrain from eating or drinking for 30 minutes following the rinsing procedure to ensure optimal efficacy.

For children under 12 years of age, it is essential to instruct them in proper rinsing techniques to minimize the risk of swallowing the rinse. Supervision may be required until the child demonstrates the ability to use the rinse without assistance. For children under 6 years of age, consultation with a dentist or physician is recommended prior to use.

Contraindications

Use is contraindicated if more than the recommended amount for rinsing is accidentally swallowed. In such cases, seek professional assistance or contact a Poison Control Center immediately.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this product.

Warnings This product is intended for use as directed. It is crucial to adhere strictly to the recommended usage guidelines to avoid potential adverse effects.

General Precautions In the event that more than the recommended amount used for rinsing is accidentally ingested, it is imperative to seek professional medical assistance or contact a Poison Control Center immediately. Prompt action is essential to ensure patient safety and mitigate any potential risks associated with accidental ingestion.

Side Effects

No adverse reactions have been reported in clinical trials or postmarketing experiences. Additionally, there are no specific warnings associated with the use of this product. As such, healthcare professionals should continue to monitor patients for any unexpected effects during treatment.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Anticavity (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be instructed to keep the product out of reach of children. In the event that more than the recommended amount for rinsing is accidentally swallowed, professional assistance should be sought or a Poison Control Center contacted immediately.

For pediatric patients aged 6 years and older, the recommended usage is once daily after brushing teeth with toothpaste. Patients should vigorously swish 10 milliliters of the rinse between their teeth for 1 minute and then spit it out. It is important that the rinse is not swallowed, and patients should refrain from eating or drinking for 30 minutes after rinsing. Children under 12 years of age should be instructed in proper rinsing techniques to minimize the risk of swallowing, and supervision is advised until they are capable of using the product without assistance.

For children under 6 years of age, consultation with a dentist or doctor is recommended prior to use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established. Caution is advised as the effects on fetal development are not well studied, and potential risks to the fetus are not detailed in the prescribing information. Pregnant patients should consult a healthcare provider before use to discuss any potential risks and benefits. No specific dosage modifications for pregnant individuals are provided.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there is no information available concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is essential that patients with reduced creatinine clearance are closely monitored throughout the treatment process. Additionally, renal function tests should be performed prior to and during treatment in these patients to ensure appropriate management and safety.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential risks associated with excessive administration of the medication.

In cases where an overdose is suspected, it is recommended that healthcare providers assess the patient's clinical status and consider the following general management strategies:

Recommended Actions

1. Immediate Assessment: Conduct a thorough evaluation of the patient's vital signs and overall clinical condition.

2. Supportive Care: Initiate supportive measures as necessary, which may include monitoring of cardiac and respiratory function.

3. Symptomatic Treatment: Address any symptoms that may arise as a result of the overdose, tailoring interventions to the specific clinical presentation.

Potential Symptoms While specific symptoms related to this medication's overdosage are not detailed, healthcare professionals should be aware of common signs associated with overdose scenarios, which may include but are not limited to:

• Altered mental status

• Gastrointestinal disturbances

• Cardiovascular irregularities

Management Procedures In the event of an overdose, it is advisable to contact a poison control center or a medical toxicologist for guidance on further management. The healthcare provider should also consider the need for additional interventions, such as activated charcoal administration, if appropriate and within the timeframe for effective intervention.

Healthcare professionals are encouraged to report any cases of suspected overdosage to the relevant authorities to contribute to the ongoing assessment of the medication's safety profile.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients that if more than the recommended amount used for rinsing is accidentally swallowed, it is crucial to seek professional assistance or contact a Poison Control Center immediately. This information is essential for ensuring patient safety and prompt action in case of accidental ingestion.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature to maintain its integrity and efficacy. No special handling requirements are necessary beyond standard storage practices.

Additional Clinical Information

Patients should be instructed to take the medication orally, once a day, after brushing their teeth with toothpaste. Clinicians should emphasize the importance of good rinsing habits for children under 12 years of age to minimize swallowing, and they should supervise these children as necessary until they are capable of using the medication without supervision.

Drug Information (PDF)

This file contains official product information for Anticavity, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)